Pharmacovigilance – Products

Avacta Group plc announces that AVA6000 continues to show a very favorable safety profile in the fourth dose cohort of the ALS-6000-101 dose escalation phase 1 clinical trial.

Thermo Fisher Scientific Inc. received R&D 100 Awards from R&D World Magazine for two of its most recently launched analytical instruments.

Personalis has announced a collaboration with UC San Francisco that will deploy a personalized liquid biopsy-based research use only assay for a study of patients with colorectal cancer.

Glycosylation is a common post-translational modification (PTM) that plays a critical role in antibody effector functions. Comprehensive characterization of N- and O-linked glycosylation in protein therapeutics is essential for ensuring drug safety and efficacy.

PerkinElmer’s Oxford Immunotec has announced the U.S. Food and Drug Administration has approved the use of the T-Cell Select™ reagent kit for the automation of its T-SPOT®.TB test workflow for in vitro diagnostic use by certified laboratories.

Molecular Devices, LLC. and HeartBeat.bio AG, a biotech company developing cardiac organoids for drug discovery, have entered into a co-development agreement.

Multisite study will test sonodynamic therapy in pediatric patients with diffuse intrinsic pontine glioma (DIPG).

Voltron Therapeutics, Inc. has announced that data from the previously announced Study ‘098 demonstrated clear Proof-of Concept for VTX-067 in the treatment of HPV-related cancers.

Deep Breath Intelligence is pleased to announce the launch of a simple breath test that can provide reliable estimates of circulating concentrations of the antiseizure medication valproic acid to aid patient management.

VectorBuilder Inc. has announced its plan to invest $30 million to build an "AAV Superbank" for the research and drug discovery community.